Clinical trials: sponsored by Ruijin Hospital
Acute Myeloid Leukemia
Study of SA+X in the Treatment of Newly Diagnosed AML
This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with…
- Trial name
- NCT07548710
- Testing
- Anthracycline, Ivosidenib, Gilteritinib
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Ruijin Hospital
Rectal Cancer, Colon Cancer
Learning Curve of SILS in CRC
Based on the data analysis of the General Surgery Department (Northern Department) of Ruijin Hospital from December 2013 to June 2021, we conducted a retrospective cohort study.
- Conditions
- Rectal Cancer, Colon Cancer, Single Port Laparoscopy
- Trial name
- SILS (NCT07736131)
- Volunteers
- 280 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
This study aims to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome, subcutaneous cytarabine and G-CSF combined with venetoclax (CMG+Ven) versus azacitidine combined with venetoclax (VA) in the treatment of…
- Trial name
- NCT07735117
- Testing
- Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF)
- Volunteers
- 168 people
- Sponsor
- Ruijin Hospital
Gastric Cancer Stage IV, Peritoneal Metastases
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
- Trial name
- NCT06519591
- Testing
- Cadonilimab, LM-302, S-1, paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Mantle Cell Lymphoma (MCL)
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
This multicenter, open-label, trial aims to evaluate the efficacy and safety of orelabrutinib plus lisaftoclax and rituximab in patients with high-risk mantle cell lymphoma (MCL).
- Trial name
- NCT07272499
- Testing
- Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Ruijin Hospital
Bronchiectasis Adult
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis).
- Trial name
- NCT06987214
- Testing
- REGEND001 Autologous Basal Layer Stem Cell Suspension
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Interstitial Lung Disease (ILD)
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study
This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD).
- Trial name
- NCT06998706
- Testing
- REGEND001 Autologous Basal Layer Stem Cell Suspension
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Laryngoscopy, Training
Artificial Intelligence-Assisted Training for Novice Physicians in Electronic Nasopharyngolaryngoscopy
This study aims to evaluate whether an artificial intelligence-assisted monitoring system can improve the training of novice physicians in electronic nasopharyngolaryngoscopy.
- Trial name
- NCT07726641
- Testing
- Artificial Intelligence-Assisted Monitoring System for Electronic Nasopharyngolaryngoscopy
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Cerebral Small Vessel Disease
The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital
The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are: How does neurovascular coupling change during the progression of…
- Trial name
- NCT07726654
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Ischemic Heart Disease
Functional ComprEhensive AssessmenT by IVUS Reconstruction in Patients With Suspected IschEmic Heart Disease (FEATURE)
Investigating the diagnostic accuracy of online Ultrasonic Flow Ratio (UFR) assessment to identify hemodynamically significant coronary stenosis in patients with suspected ischemic heart disease using angiography-derived…
- Trial name
- NCT05694065
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701…
- Trial name
- NCT07384234
- Testing
- SHR-1701, Capecitabine, S-1
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Follicular Lymphoma ( FL)
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
This study intends to conduct a prospective, multicenter, open-label, randomized controlled clinical trial to systematically evaluate the efficacy and safety of the orelabrutinib plus obinutuzumab and lenalidomide (RO2) regimen…
- Trial name
- NCT07719855
- Testing
- Orelabrutinib, obinutuzumab, Lenalidomide
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Ruijin Hospital
Interstitial Lung Disease (ILD), Healthy Volunteers
The Safety and PK Study of Inhaled ICF004 in Healthy Chinese Volunteers
The goal of this clinical trial is to learn about the safety of an inhaled study drug called ICF004 in healthy adults. ICF004 is being created to treat progressive lung scarring in the future.
- Trial name
- ICF004-INH (NCT07719218)
- Testing
- ICF004, Pacebo
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Large B-Cell Lymphoma (LBCL)
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
This is a prospective, open-label, multicenter, randomized controlled study in older treatment-naive patients with LBCL. Participants will be stratified into different risk groups using an AI-based multimodal model.
- Trial name
- PRAISE (NCT07717177)
- Testing
- Polatuzumab Vedotin, Rituximab (R), Zanubrutinib
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Chronic Obstructive Pulmonary Disease (COPD)
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chronic Obstructive Pulmonary Disease (COPD): A Translational Application Study
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT06946953
- Testing
- P63+ lung progenitors
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Peripheral T-cell Lymphoma (PTCL)
New Genotype-guided Treatment in Newly Diagnosed PTCL
This is a phase I/II study evaluate the safety and efficacy targeted agents in combination with standard CHOP in new genotypic subtypes in treatment naive peripheral T-cell lymphoma. Phase I is to confirm RP2D of targeted agent.
- Trial name
- G08 (NCT07706959)
- Testing
- Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Interstitial Lung Disease (ILD), Healthy Volunteers
A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease
This Phase 1 clinical trial investigates the pharmacokinetics and safety profile of single-dose inhaled RJ026 in healthy volunteers and patients with interstitial lung disease (ILD).
- Trial name
- NCT06992661
- Testing
- RJ026 inhaled powder, Oral RJ026 capsules
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
Multi center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.
- Trial name
- NCT07705308
- Testing
- Radiation (Very low dose), Radiation (Standard)
- Where
- 3 sites in China
- Volunteers
- 140 people
- Sponsor
- Ruijin Hospital
Influenza
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.
This randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Onradivir Tablets in participants aged 12 to 17 years with influenza A virus infection.
- Trial name
- NCT07229547
- Testing
- Onradivir tablet
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Heart Failure, Heart Failure and Reduced Ejection Fraction
Biomarkers for Left Ventricular Reverse Remodeling in Heart Failure (REVERT-HF)
Heart failure is a serious condition where the heart cannot pump blood effectively. Some patients with severe heart failure (known as heart failure with reduced ejection fraction, or HFrEF) can experience significant improvement…
- Trial name
- REVERT-HF (NCT07701876)
- Where
- China
- Volunteers
- 1,740 people
- Sponsor
- Ruijin Hospital Luwan Branch